AIRNA has successfully closed an oversubscribed $60 million financing round. This latest funding brings the total Series A financing to $90 million, underscoring the robust investor confidence in AIRNA’s innovative approach to treating rare and common diseases.
Leading the financing round was Forbion, with significant participation from Ono Venture Investment, Alexandria Venture Investments, and other new investors. Existing investors, including ARCH Venture Partners and ND Capital, also contributed to the round. The capital raised will be pivotal in advancing AIRNA’s lead product candidate into clinical trials and expanding its therapeutic pipeline.
Kris Elverum, President and CEO of AIRNA, expressed optimism about the funding milestone, stating, “This Series A financing brings together a distinctive syndicate of investors to support AIRNA’s vision of transforming lives by realizing the therapeutic potential of base editing for the masses. We are focused on bringing our first drug candidate to the clinic next year and advancing our platform to unlock targets that are inaccessible by other modalities.”
Founded with support from ARCH Venture Partners, AIRNA aims to revolutionize RNA therapeutics through its RESTORE+™ platform. This platform enhances oligonucleotide sequence, chemistry, and delivery to achieve precise, efficient, and safe RNA editing. The company’s leading product candidate targets alpha-1 antitrypsin deficiency, a genetic disorder linked to severe lung and liver diseases.
In addition to the funding news, AIRNA announced the appointment of Josh Brumm, General Partner at Forbion, to its Board of Directors. Brumm, formerly the CEO of Dyne Therapeutics, brings a wealth of experience in developing oligonucleotide-based medicines.
“AIRNA has a differentiated approach to delivering life-changing outcomes for patients with AATD and other severe diseases,” Brumm noted. “We are excited to support AIRNA’s exceptional management team and collaborate across continents to build a leading genetic medicines company.”